JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB195810

Anti-TNFAIP8 抗体 [EPR10058(3)]

Anti-TNFAIP8 antibody [EPR10058(3)]

Be the first to review this product! Submit a review

|

(6 Publications)

Rabbit Recombinant Monoclonal TNFAIP8 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 6 publications.

別名を表示する

Tumor necrosis factor alpha-induced protein 8, TNF alpha-induced protein 8, Head and neck tumor and metastasis-related protein, MDC-3.13, NF-kappa-B-inducible DED-containing protein, SCC-S2, TNF-induced protein GG2-1, NDED, TNFAIP8

3 Images
Immunoprecipitation - Anti-TNFAIP8 antibody [EPR10058(3)] (AB195810)
  • IP

Supplier Data

Immunoprecipitation - Anti-TNFAIP8 antibody [EPR10058(3)] (AB195810)

TNFAIP8 was immunoprecipitated from K562 (Human chronic myelogenous leukemia cells from bone marrow) whole cell extract with ab195810 at 1/70 dilution (Lane 2). Western blot was performed from the immunoprecipitate using ab195810 at 1/1000 dilution. Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG, was used as secondary antibody at 1/1500 dilution. Lane 1 : K562 whole cell extract (Input) 10μg. Lane 2 : ab195810 IP in K562 whole cell extract. Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab195810 in K562 whole cell extract.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.

All lanes:

Immunoprecipitation - Anti-TNFAIP8 antibody [EPR10058(3)] (ab195810)

Predicted band size: 23 kDa

false

Western blot - Anti-TNFAIP8 antibody [EPR10058(3)] (AB195810)
  • WB

Supplier Data

Western blot - Anti-TNFAIP8 antibody [EPR10058(3)] (AB195810)

Blocking/Dilution buffer : 5% NFDM/TBST.

Based on the sequence analysis, ab195810 recognizes three isoforms with the predicted MWs of 23KDa, 22KDa and 22KDa, respectively.

All lanes:

Western blot - Anti-TNFAIP8 antibody [EPR10058(3)] (ab195810) at 1/1000 dilution

All lanes:

Human fetal spleen lysate at 20 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 23 kDa

Observed band size: 19 kDa,21 kDa

false

Western blot - Anti-TNFAIP8 antibody [EPR10058(3)] (AB195810)
  • WB

Supplier Data

Western blot - Anti-TNFAIP8 antibody [EPR10058(3)] (AB195810)

Blocking/Dilution buffer : 5% NFDM/TBST.

Based on the sequence analysis, ab195810 recognizes three isoforms with the predicted MWs of 23KDa, 22KDa and 22KDa, respectively.

All lanes:

Western blot - Anti-TNFAIP8 antibody [EPR10058(3)] (ab195810) at 1/1000 dilution

Lane 1:

K562 cell lysate at 20 µg

Lane 2:

A549 cell lysate at 20 µg

Lane 3:

A431 cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 23 kDa

Observed band size: 19 kDa,21 kDa

false

関連する標識済み抗体及び組成の異なる製品 (1)

  • Carrier free

    Anti-TNFAIP8 antibody [EPR10058(3)] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR10058(3)

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB, IP

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/70", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" } } }

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Conditional Ambient
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Acts as a negative mediator of apoptosis and may play a role in tumor progression. Suppresses the TNF-mediated apoptosis by inhibiting caspase-8 activity but not the processing of procaspase-8, subsequently resulting in inhibition of BID cleavage and caspase-3 activation.
See full target information Tumor necrosis factor alpha-induced protein 8

文献 (6)

Recent publications for all applications. Explore the full list and refine your search

International journal of genomics 2021:3997045 PubMed34901263

2021

circHUWE1 Exerts an Oncogenic Role in Inducing DDP-Resistant NSCLC Progression Depending on the Regulation of miR-34a-5p/TNFAIP8.

Applications

Unspecified application

Species

Unspecified reactive species

Xueliang Yang,Quan Sun,Yongming Song,Wenli Li

Cancer research 82:221-234 PubMed34625422

2021

Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Amy C Mandigo,Ayesha A Shafi,Jennifer J McCann,Wei Yuan,Talya S Laufer,Denisa Bogdan,Lewis Gallagher,Emanuela Dylgjeri,Galina Semenova,Irina A Vasilevskaya,Matthew J Schiewer,Chris M McNair,Johann S de Bono,Karen E Knudsen

Endocrine connections 10:471-483 PubMed33764889

2021

Long noncoding RNA DLEU2 drives the malignant behaviors of thyroid cancer through mediating the miR-205-5p/TNFAIP8 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Jiwen Yang,Yayin Huang,Bohan Dong,Yunhai Dai

Oncology letters 21:118 PubMed33376549

2020

Expression of TIPE family members in human colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Mengya Zhong,Zhijian Chen,Yang Yan,Argen Bahet,Xin Cai,Huiyu Chen,Honggang Ran,Kaiyong Qu,Zhaopu Han,Guohong Zhuang,Shifeng Zhang,Yinan Wang

Journal of Cancer 11:3061-3071 PubMed32226521

2020

TNFAIP8 promotes the migration of clear cell renal cell carcinoma by regulating the EMT.

Applications

Unspecified application

Species

Unspecified reactive species

Mengya Zhong,Maoshu Zhu,Yu Liu,Ying Lin,Lianghai Wang,Yuhan Ye,Huiyu Chen,Yan Yang,Guohong Zhuang,Jiyi Huang

Oncology letters 17:4667-4674 PubMed30944654

2019

TNFAIP8 promotes cisplatin resistance in cervical carcinoma cells by inhibiting cellular apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Suxia Wu,Weihua Li,Zhenghui Wu,Tianran Cheng,Ping Wang,Na Li,Xiaonan Liang,Mengmeng Chi,Shuman Zhang,Yuanfang Ma,Yanyun Li,Lihui Chai
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com